Purdue Research Foundation

Other

Mohamed Seleem

Mingji Dai

Haroon Taj Mohammad

Dexter Cameron Davis

Mark Stanley Cushman

Jean Anne Chmielewski

Abdelrahman S Mayhoub

Ji-Xin Cheng

Herman O Sintim

Clement Opoku-Temeng

George Naclerio

Xianglin Yin

Daniel Patrick Flaherty

Jie Hui

Pu-Ting Dong

Tim Jonathan Schmidt

Calvin Nicklaus Steussy, Jr

Victor W Rodwell

Cynthia Stauffacher

Mark Alfred Lipton

Nader Abutaleb

Weili Hong

Kwaku Kyei-Baffour

Jatinder Kaur

Xufeng Cao

The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant, vancomycin-intermediate and vancomycin-resistant, vancomycin-resistantand. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

Benzamide antibacterial agents

The invention described herein generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as a narrow spectrum antibiotics against drug resistant bacteria and methods for treating those infection diseases in mammals using the described carbonic anhydrase inhibitors or a pharmaceutical formulation thereof.

Carbonic anhydrase inhibitors and antibiotics against multidrug resistant bacteria

A method to treat a patient with ainfection comprising administering a therapeutically effective amount of diiodohydroxyquinoline, with or without one or more anti-infective agents.

Diiodohydroxyquinoline for the treatment of clostridium difficile infection

A method for the determination of antibiotic susceptibility through stimulated Raman scattering microscopy is disclosed. The method utilizes a imaging apparatus adapted to collect a laser signal through a sample having a bacteria for imaging the metabolism of the sample. The sample can be manipulated with an antibiotic for imaging to determine the susceptibility of a bacteria to the provided antibiotic.

Method for the determination of antibiotic susceptibility through stimulated Raman metabolic imaging

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of

Aryl isonitriles as a new class of antimicrobial compounds

Methicillin-resistant(MRSA) possesses array of strategies to evade antibiotics through mutational inactivation, hiding inside host immune cells or concealing inside the biofilm in a sessile form. We report a drug-free approach to eradicate MRSA through blue-light bleaching of staphyloxanthin (STX), an anti-oxidative carotenoid residing inside the cell membrane of. The photobleaching process, uncovered through a transient absorption imaging study and quantitated by mass spectrometry, decomposes STX and sensitizes MRSA to reactive oxygen species attack. Consequently, photobleaching using low-level blue light exhibits high-level synergy when combined with low-concentration of hydrogen peroxide. Antimicrobial effectiveness of this synergistic therapy is validated in MRSA culture, MRSA-infected macrophage cells, biofilm, and a mouse wound infection model. Collectively, these findings highlight broad applications of STX photobleaching for MRSA-infected diseases.

Method and device for annihilation of methicillin-resistant

The present disclosure relates to novel antibacterial cell-penetrating peptides and derivatives, and methods to make and use the novel antibacterial cell-penetrating peptides and derivatives. The novel antibacterial cell-penetrating peptides of the present invention with shorter linker between a pyrrolidine ring and a guanidine group provide unexpectedly higher potency against a broader scope of bacterial.

Antibacterial cell-penetrating peptides

The present disclosure relates to novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide, and methods to make and use the novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide.

Cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide

Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are, andgiven their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species ofand. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 &#x3bc;M. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 &#x3bc;M.

Aryl isonitrile compounds as a new class of potent, broad-spectrum antifungal compounds

Series of 2-phenyl-4-methylthiazole analogs are disclosed as potential therapeutic agents for the treatment of bacterial infections, especially methicillin-resistant(MRSA) related infections. A method for the treatment of MRSA-related infections is also claimed.

Phenylthiazoles and uses thereof

Disclosed herewith is drug repurposing efforts that lead to the discovery of prior non-antibiotic drugs can be used in clinical applicable ranges to treat patients of bacterial infection. These repurposed drug can be used either alone or in combination with traditional antibiotic drugs to treat bacterial strains that may develop or already have developed drug resistance.

Growing community of inventors

West Lafayette, IN, United States of America

Mohamed Seleem